![]() As one of our contract manufacturers since November 2020, Aspen has been a significant supplier within the Johnson & Johnson global network. To date, Johnson & Johnson has shipped more than 200 million vaccine doses to Africa through a combination of our advance purchase agreements with the African Vaccine Acquisition Trust, South Africa and Gavi, the Vaccine Alliance, on behalf of the COVAX Facility, along with government donations. We’re proud to take our long-standing collaboration with Aspen to the next level, to continue to address the COVID-19 threat and lay the groundwork for a healthier, more secure future for people in Africa.” “We initiated clinical trials in all regions of the world to generate evidence across multiple geographies and diverse, at-risk populations and forged a strategic partnership with Aspen in Africa and others to manufacture our vaccine globally. “From the outset of this pandemic we aimed to develop a simple-to-use and accessible vaccine that could be transported around the world through standard vaccine distribution channels,” said Martin Fitchet, M.D., Head of Global Public Health, Johnson & Johnson, Cilag GmbH International. Our response to the COVID-19 pandemic has been guided by the conviction that unless everyone is safe, no one is safe, which is why we worked to develop and deliver a vaccine that can protect the health of everyone, everywhere. Currently, only about 12 percent of people in Africa are fully vaccinated, which is well below the World Health Organization’s target of 70 percent population coverage for all countries. ![]() Merck to help produce Johnson & Johnson's COVID-19 vaccine BARDA to provide Merck with funding to expand Merck's manufacturing capacity for COVID-19 vaccines and medicines.NEW BRUNSWICK, NJ (March 8, 2022) – Johnson & Johnson (NYSE: JNJ) (the Company) today announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., and manufacturer Aspen SA Operations (Pty) Ltd, based in South Africa, to enable the first COVID-19 vaccine to be manufactured and made available by an African company for people living in Africa, with the goal of increasing COVID-19 vaccination rates across the continent.Įxpanding global vaccination coverage is critically important to controlling the COVID-19 pandemic and reducing the risk of emergence of new SARS-CoV-2 variants. Department of Health & Human Services and commitment to supply one billion vaccines worldwide for emergency pandemic use. Vaccine candidate for COVID-19 landmark new partnership with U.S. FDA and CDC lift recommended pause on Johnson & Johnson (Janssen) COVID-19 vaccine use following thorough safety review. Updated recommendations from the Advisory Committee on Immunization Practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients - United States, April 2021. Fact sheet for recipients and caregivers: emergency use authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19). Selected adverse events reported after COVID-19 vaccination.įood & Drug Administration. Coronavirus (COVID-19) update.Ĭenters for Disease Control and Prevention. Coronavirus (COVID-19) update: FDA limits use of Janssen COVID-19 vaccine to certain individuals.įood & Drug Administration. Stay Up to Date with COVID-19 Vaccines Including Boosters.įood & Drug Administration. government for 100 million doses of investigational COVID-19 vaccine.Ĭenters for Disease Control and Prevention. Johnson & Johnson announces agreement with U.S. COVID-19 Vaccinations in the United States. doi:10.1056/NEJMc2202061Ĭenters for Disease Control and Prevention. Effectiveness of and BNT162b2 Vaccines against Omicron Variant in South Africa. CDC endorses ACIP’s updated COVID-19 vaccine recommendations. doi:10.1056/NEJMoa2101544Ĭenters for Disease Control and Prevention. Safety and efficacy of single-dose vaccine against Covid-19. Positive new data for Johnson & Johnson single-shot COVID-19 vaccine on activity against Delta variant and long-lasting durability of response. Johnson & Johnson prepares to resume Phase 3 ENSEMBLE trial of its Janssen COVID-19 vaccine candidate in the U.S. Fact sheet for healthcare providers administering vaccine (vaccination providers): Emergency Use Authorization (EUA) of the Janssen COVID-19 vaccine to prevent coronavirus disease 2019 (COVID-19).ĭepartment of Health and Human Services.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |